TY  - JOUR
AU  - Unglaub, Julia Marie
AU  - Schlenk, Richard
AU  - Middeke, Jan M
AU  - Krause, Stefan W
AU  - Kraus, Sabrina
AU  - Einsele, Hermann
AU  - Kramer, Michael
AU  - Zukunft, Sven
AU  - Kauer, Joseph
AU  - Renders, Simon
AU  - Katelari, Elena
AU  - Schliemann, Christoph
AU  - Pabst, Caroline
AU  - Luft, Thomas
AU  - Dreger, Peter
AU  - Röllig, Christoph
AU  - Bornhäuser, Martin
AU  - Müller-Tidow, Carsten
AU  - Sauer, Tim
TI  - Venetoclax-based salvage therapy as bridge-to-transplant is feasible and effective in patients with relapsed/refractory AML.
JO  - Blood advances
VL  - 9
IS  - 2
SN  - 2473-9529
CY  - Washington, DC
PB  - American Society of Hematology
M1  - DKFZ-2024-01886
SP  - 375-385
PY  - 2025
N1  - 2025 Jan 28;9(2):375-385
AB  - The BCL2-inhibitor Venetoclax (VEN) in combination with hypomethylating agents (HMA) has been approved for first-line treatment of acute myeloid leukemai (AML) patients ineligible for intensive treatment. Emerging Data suggest that VEN containing treatment strategies may also be effective in relapsed/refractory (R/R) AML, however, comparative studies with conventional treatment strategies for medically fit patients as a bridge-to transplant strategy are limited. Using propensity score matching (PSM) analysis, we compared 37 R/R AML patients, who received VEN-based salvage therapy as bridge to allogeneic hematopoietic cell transplantation (allo-HCT) with 90 patients from the German Study Alliance Leukemia (SAL) AML registry, who were treated with non-VEN-containing salvage therapy according to their treating physician's choice (TPC) including intensive and non-intensive protocols. The overall response rate (ORR=CR+CRi) among all VEN patients was significantly higher compared to the TPC control cohort (62
LB  - PUB:(DE-HGF)16
C6  - pmid:39293081
DO  - DOI:10.1182/bloodadvances.2024013086
UR  - https://inrepo02.dkfz.de/record/293338
ER  -